| 1.03 0 (0%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.52 | 1-year : | 1.75 |
| Resists | First : | 1.3 | Second : | 1.5 |
| Pivot price | 1.08 |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.02 |
MA(20) : | 1.12 |
| MA(100) : | 1.57 |
MA(250) : | 2.76 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 10.5 |
| RSI | RSI(14): 42.9 | |||
| 52-week | High : | 6.09 | Low : | 0.79 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AIMD ] has closed above bottom band by 30.0%. Bollinger Bands are 68.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.03 - 1.04 | 1.04 - 1.04 |
| Low: | 1 - 1 | 1 - 1.01 |
| Close: | 1.02 - 1.03 | 1.03 - 1.04 |
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Mon, 08 Apr 2024
Ainos files to sell 4.43M common shares for holders (NASDAQ:AIMD) - Seeking Alpha
Mon, 11 Mar 2024
Ainos Inc (AIMD) Down 13.66% in Premarket Trading - InvestorsObserver
Sun, 10 Mar 2024
We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt - Simply Wall St
Fri, 08 Mar 2024
Should You Hold Ainos Inc (AIMD) Stock Friday Morning? - InvestorsObserver
Fri, 08 Mar 2024
Why Is Ainos (AIMD) Stock Up 153% Today? - InvestorPlace
Mon, 04 Mar 2024
Ainos Inc (AIMD) Up 88.57% in Premarket Trading - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 2.56e+006 (%) |
| Held by Institutions | 54.7 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.05e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -27 % |
| Return on Assets (ttm) | 202.1 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 122110 % |
| Gross Profit (p.s.) | -66.74 |
| Sales Per Share | -31.72 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.28 |
| Dividend | 0 |
| Forward Dividend | 78880 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|